** Brokerage BOBCaps initiates coverage on India's Anthem Biosciences ANTH.NS with "buy" rating, sets PT at 835 rupees
** Shares of ANTH down 1.5% to 653 rupees amid broader market downturn; Nifty 50 .NSEI down 2%
** Brokerage says co has gamut of innovative modalities
** Co's industry-high margin is expected to sustain, given the ramp up in peptides capacity, including backward integration and installing unit 4 for small molecules- BOBCaps
** Being one of the few backward-integrated peptide manufacturers, gives it cost edge over China competitors in GLP- BOBCaps
** Molecules sales are further likely to grow by $21.4 billion by CY29, indicating a CAGR of 13.5% CAGR from CY24-29- BOBCaps
** ANTH rated "strong buy" on avg by 6 analysts covering it; median PT at 772 rupees- data compiled by LSEG
** YTD, ANTH gains 2%
(Reporting by Komal Salecha in Bengaluru)
((Komal@thomsonreuters.com))